Eli Lilly and Co (LLY) Forecasted to Earn FY2019 Earnings of $4.74 Per Share

Eli Lilly and Co (NYSE:LLY) – Stock analysts at Leerink Swann issued their FY2019 EPS estimates for shares of Eli Lilly and in a research report issued on Monday. Leerink Swann analyst S. Fernandez expects that the company will post earnings per share of $4.74 for the year. Leerink Swann has a “Outperform” rating on the stock. Leerink Swann also issued estimates for Eli Lilly and’s FY2020 earnings at $4.98 EPS and FY2021 earnings at $5.41 EPS.

Several other analysts have also recently weighed in on LLY. Jefferies Group LLC restated a “buy” rating and set a $97.00 price objective (up previously from $95.00) on shares of Eli Lilly and in a research report on Saturday, March 11th. Vetr cut shares of Eli Lilly and from a “hold” rating to a “sell” rating and set a $74.30 price objective on the stock. in a research report on Tuesday, January 31st. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a research report on Tuesday, January 24th. Credit Suisse Group AG restated a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, March 21st. Finally, BMO Capital Markets restated a “market perform” rating and set a $73.00 price objective (up previously from $70.00) on shares of Eli Lilly and in a research report on Wednesday, February 1st. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Eli Lilly and currently has an average rating of “Buy” and a consensus target price of $88.70.

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

COPYRIGHT VIOLATION NOTICE: This news story was posted by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.themarketsdaily.com/2017/04/21/eli-lilly-and-co-lly-forecasted-to-earn-fy2019-earnings-of-4-74-per-share.html.

Shares of Eli Lilly and (NYSE:LLY) traded down 0.06% during midday trading on Wednesday, hitting $81.89. The stock had a trading volume of 3,499,417 shares. The company has a market cap of $86.06 billion, a price-to-earnings ratio of 31.74 and a beta of 0.30. Eli Lilly and has a 52 week low of $64.18 and a 52 week high of $86.72. The stock’s 50-day moving average price is $84.25 and its 200 day moving average price is $77.93.



Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, January 31st. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.98 by $0.03. Eli Lilly and had a return on equity of 24.74% and a net margin of 12.90%. The firm had revenue of $5.76 billion for the quarter, compared to the consensus estimate of $5.54 billion. During the same quarter in the prior year, the firm earned $0.78 EPS. The company’s revenue was up 7.2% on a year-over-year basis.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction dated Thursday, March 30th. The shares were sold at an average price of $84.67, for a total value of $17,780,700.00. Following the transaction, the insider now owns 124,690,804 shares in the company, valued at $10,557,570,374.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Derica W. Rice sold 11,162 shares of the business’s stock in a transaction dated Friday, February 3rd. The shares were sold at an average price of $77.14, for a total transaction of $861,036.68. Following the completion of the transaction, the executive vice president now owns 58,443 shares in the company, valued at approximately $4,508,293.02. The disclosure for this sale can be found here. In the last quarter, insiders sold 688,162 shares of company stock worth $55,440,777. 0.20% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in LLY. Tarbox Group Inc. boosted its position in Eli Lilly and by 0.7% in the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock worth $124,000 after buying an additional 11 shares during the last quarter. First Citizens Bank & Trust Co. boosted its position in Eli Lilly and by 0.3% in the third quarter. First Citizens Bank & Trust Co. now owns 5,920 shares of the company’s stock worth $476,000 after buying an additional 18 shares during the last quarter. Strategic Financial Group LLC boosted its position in Eli Lilly and by 0.5% in the third quarter. Strategic Financial Group LLC now owns 3,449 shares of the company’s stock worth $277,000 after buying an additional 18 shares during the last quarter. Enterprise Financial Services Corp boosted its position in Eli Lilly and by 0.9% in the third quarter. Enterprise Financial Services Corp now owns 2,150 shares of the company’s stock worth $173,000 after buying an additional 20 shares during the last quarter. Finally, Regentatlantic Capital LLC boosted its position in Eli Lilly and by 0.7% in the third quarter. Regentatlantic Capital LLC now owns 3,229 shares of the company’s stock worth $259,000 after buying an additional 21 shares during the last quarter. Hedge funds and other institutional investors own 75.15% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply